Announced details
Drug discovery; exploration of new indications (drug repositioning); endocrine, cardiovascular, renal and metabolic fields; rare diseases and obesity
DDAIF has been adopted by multiple major pharmaceutical companies and has built up a track record.
FRONTEO and スコヒアファーマ entered into an agreement concerning the exploration of new indications. FRONTEO subscribed for shares issued by スコヒアファーマ in a private placement and made an investment in the company.
Head office: Fujisawa, Kanagawa Prefecture; Representative Director and President: Watanabe Masanori (渡部正教). A drug discovery startup specializing in the endocrine, cardiovascular, renal and metabolic fields. Established in 2017. The company handles the full process from identifying drug discovery targets through clinical development, with a focus on rare diseases and obesity.
KIBIT-related technologies have obtained a total of 21 patents in Japan, Europe, the United States and South Korea. Validity periods and individual patent numbers: Not disclosed
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, KIBIT |
| Counterparty | スコヒアファーマ Co., Ltd. |
| Counterparty overview | Head office: Fujisawa, Kanagawa Prefecture; Representative Director and President: Watanabe Masanori (渡部正教). A drug discovery startup specializing in the endocrine, cardiovascular, renal and metabolic fields. Established in 2017. The company handles the full process from identifying drug discovery targets through clinical development, with a focus on rare diseases and obesity. |
| Relationship with the Company | FRONTEO and スコヒアファーマ entered into an agreement concerning the exploration of new indications. FRONTEO subscribed for shares issued by スコヒアファーマ in a private placement and made an investment in the company. |
| Contract Date | 28 May 2026 |
| Applicable area | Drug discovery; exploration of new indications (drug repositioning); endocrine, cardiovascular, renal and metabolic fields; rare diseases and obesity |
| Registration number and expiry date | KIBIT-related technologies have obtained a total of 21 patents in Japan, Europe, the United States and South Korea. Validity periods and individual patent numbers: Not disclosed |
| Usage history | DDAIF has been adopted by multiple major pharmaceutical companies and has built up a track record. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To explore new indications for スコヒアファーマ's compounds that are difficult to identify using conventional methods, thereby helping shorten the time and reduce the costs required for drug discovery and address unmet medical needs.